Tolebrutinib inhibited clinical non-relapsing secondary progressive MS and thus became the first drug to do this. However whilst it showed a clinical slowing of disability, it failed to have benefit in other measures. More recently a trial was done in primary progressive MS and tolebrutininb failed to affect progression. The Federal Drug Administration has said that they will not approve this drug for use in the USA yet, so I guess stocks may need to shipped to the Emirates where tolebrutinib was provisionally approved. They may give an opinion in March but the manufacture said they won’t develop the drug for primary progressive MS. Again is shows us how difficult it is to see positive effects of treatments on progressive MS…Not what you want for the end of 2025…but maybe better news for 2026.
Don’t expect me to be mystic Meg and do a look back at the year or to look forward to the next….This is not my scene…You can go to MS selfie for that. 2025 has been a strange year for me…..But I hope 2026 brings you some good news
Whats a shania..hers a clue. https://www.youtube.com/watch?v=mqFLXayD6e8
Source: multiple-sclerosis-research.org